Skip to main content

Jolla Value Stock - Dividend - Research Selection

La Jolla Pharmaceutical

ISIN: US5034596040, WKN: A1XB6B

Market price date: 23.07.2021
Market price: 3,79 USD




La Jolla Pharmaceutical Fundamental data and company key figures of the share

Annual reports in USD
Key figures 17-03-2021
Cash flow
Net operating cash flow -37.640.000
Capital Expenditures -1
Free cash flow -37.640.000
Balance sheet
Total Equity -88.087.000
Liabilities & Shareholders equity 72.243.000
Income statement
Net income -39.420.000
Eps (diluted) -1,440
Diluted shares outstanding 27.000.000
Net sales/revenue 33.420.000

Fundamental ratios calculated on: 23-07-2021

Ratios
Key figures 23-07-2021
Cash flow
P/C -2,72
   
P/FC -2,72
Balance sheet
ROI-54,57
ROE-121,93
Income statement
P/E-2,63
Div. Yield0,00%
P/B-1,16
P/S3,06


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolLJPC
Market Capitalization102.330.000,00 USD
Country
IndicesNO INDEX
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split2014-01-14,1.000000/50.000000; 2012-02-17,1.000000/100.000000; 2011-04-15,1.000000/100.000000; 2005-12-22,1.000000/5.000000
Internetwww.lajollapharmaceutical.com


Description of the company

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.lajollapharmaceutical.com